Home About Us Pipeline Expanded Access Investors & Media Contact Us BPDCN HomeAbout UsBusiness Development We are leveraging our drug development, manufacturing, and commercialization expertise to offer partners an integrated solution. We are seeking additional drug candidates for in-licensing, co-development, or acquisition to expand our drug pipeline, ultimately helping us obtain our goal to become a fully integrated biopharmaceutical company and helping patients with unmet medical needs. We welcome inquiries from potential collaborators. For more information, please contact Business Development at bd@stemline.com. About Us Management Business Development Pipeline Clinical Trials Scientific Presentations Investors & Media News & Events Contact Us BPDCN © 2021 – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use | CCPA Policy | Cookie Policy Stemline Therapeutics is a society of the Menarini Group

Home About Us Pipeline Expanded Access Investors & Media Contact Us BPDCN HomeAbout Us COMPANY OVERVIEW Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MMA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), SL-801 (felezonexor, XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing), and SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing). Stemline was founded in 2003 and is headquartered in New York City. About Us Management Business Development Pipeline Clinical Trials Scientific Presentations Investors & Media News & Events Contact Us BPDCN © 2021 – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use | CCPA Policy | Cookie Policy Stemline Therapeutics is a society of the Menarini Group